戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 if parathyroid hormone is not followed by an antiresorptive agent.
2 y, whose appearance could be prevented by an antiresorptive agent.
3 a T score of <=-2.5 for BMD), followed by an antiresorptive agent.
4 in the presence of zoledronic acid, a potent antiresorptive agent.
5  coincident with a decline in the use of the antiresorptive agents.
6 effect in patients undergoing treatment with antiresorptive agents.
7 pounds for the development of a new class of antiresorptive agents.
8  impact of a locally or systemically applied antiresorptive agent (alendronate) on simvastatin-induce
9  use parathyroid hormone in combination with antiresorptive agents and sequentially are reviewed.
10                                        Novel antiresorptive agents are being developed.
11                                          The antiresorptive agents are clearly able to preserve bone
12                                              Antiresorptive agents are widely used to treat osteoporo
13  10-year absolute fracture risk (eg, >=20%), antiresorptive agents (bisphosphonates or, if contraindi
14                                              Antiresorptive agents, especially bisphosphonates, appea
15 se findings suggest that, among women taking antiresorptive agents, greater increases in BMD are asso
16 ation, vitamin K therapy, calcimimetics, and antiresorptive agents had conflicting or inconclusive ou
17                      Therapy with individual antiresorptive agents has been shown to be effective for
18    To reduce bone loss and improve strength, antiresorptive agents have been instituted.
19 e effects of these pharmacologically diverse antiresorptive agents on gene expression in bone has not
20 ologists were less likely to be treated with antiresorptive agents (OR 0.49 [95% CI 0.28-0.86]).
21 thyroid hormone in the future, the choice of antiresorptive agent should be carefully considered.
22                                              Antiresorptive agents such as bisphosphonates are used w
23                                              Antiresorptive agents such as bisphosphonates or denosum
24 ciated bone disease are available, including antiresorptive agents such as denosumab and bisphosphona
25 nstay of treatment for osteoporosis has been antiresorptive agents (such as bisphosphonates), which h
26  be used either alone or in combination with antiresorptive agents to build new bone and reduce fract
27 rapy approaches with parathyroid hormone and antiresorptive agents to optimize efficacy outcomes.
28 reatment (parathyroid hormone followed by an antiresorptive agent), which aims to maintain or build o
29                      Alendronate (ALN) is an antiresorptive agent widely used for the treatment of os
30 e that combining parathyroid hormone with an antiresorptive agent will enhance its effect on bone min
31  is also possible that the combination of an antiresorptive agent with an anabolic agent could be mor
32 fonamides like 55 form a new class of potent antiresorptive agents with possible therapeutic use in d